Syndivia is a pioneering brand in the field of cancer therapeutics, focused on delivering the best treatment options to cancer patients. They utilize innovative technologies such as DARX™, C&R™, and APN™ to identify new drug candidates for cancer treatment and immune-oncology. Syndivia's primary goal is enhancing tumor targeting for patients with solid tumors.

Their proprietary pipeline and ADC (Antibody-Drug Conjugate) technology platform allows for the development of advanced antibody-drug conjugates with improved tumor penetration, stability in circulation, and superior efficacy. This targeted approach harnesses the unique properties of DAR1 antibody-drug conjugates, offering enhanced treatment options for cancer patients. Syndivia's visionary science pipeline includes lead programs like SDV1001, targeting K-Ras mutant malignancies, and SDV2102, for mCRPC.

In addition to their proprietary drug candidates, Syndivia collaborates on multiple preclinical programs with partners. Supported by a distinguished team, including a board of directors and a scientific advisory board, Syndivia continues to make significant advancements in the field of cancer therapeutics. For the latest news and press releases, visit their website.

Syndivia is located at 8 allée Gaspard Monge, Strasbourg, France